Fourteen‐Day Tegoprazan–Amoxicillin Dual Therapy as the First‐Line Treatment of Helicobacter pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial.

MLA

Kong, Qingzhou, et al. “Fourteen‐Day Tegoprazan–Amoxicillin Dual Therapy as the First‐Line Treatment of Helicobacter Pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial.” Helicobacter, vol. 29, no. 3, May 2024, pp. 1–8. EBSCOhost, https://doi.org/10.1111/hel.13098.

APA

Kong, Q., Mirza, I. A., Zhang, X., Song, X., Li, X., Zhang, Q., Xu, L., Guo, Y., Yu, Y., Zuo, X., Li, Y., & Li, Y. (2024). Fourteen‐Day Tegoprazan–Amoxicillin Dual Therapy as the First‐Line Treatment of Helicobacter pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial. Helicobacter, 29(3), 1–8. https://doi.org/10.1111/hel.13098

Chicago

Kong, Qingzhou, Iqtida Ahmed Mirza, Xiaoqian Zhang, Xiaohui Song, Xiaowei Li, Qiumei Zhang, Lidong Xu, et al. 2024. “Fourteen‐Day Tegoprazan–Amoxicillin Dual Therapy as the First‐Line Treatment of Helicobacter Pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial.” Helicobacter 29 (3): 1–8. doi:10.1111/hel.13098.